Inovio Pharmaceu Stock Price, News & Analysis

INOVIO (NASDAQ: INO), a biotechnology company, has announced its participation in multiple upcoming scientific conferences to present data on its lead product candidate INO-3107 for Recurrent Respiratory Papillomatosis (RRP) and next-generation DNA medicine technology.

The company has initiated a rolling Biologics License Application (BLA) submission for INO-3107, with plans to complete the submission in H2 2025 and targeting FDA file acceptance by year-end. The presentations will take place across various conferences including the American Academy of Otolaryngology Annual Meeting, World Vaccine Congress Europe, and ESMO Congress.

Additionally, INOVIO will present the first preclinical data on DNA-encoded protein technology (DPROT) for Hemophilia A and showcase developments in DNA-encoded monoclonal antibody (DMAb) technology.

INOVIO (NASDAQ: INO) announced FDA's agreement to their rolling submission timeline for the Biologics License Application (BLA) for INO-3107, a treatment for adults with Recurrent Respiratory Papillomatosis (RRP). The company plans to complete the BLA submission in the coming months and will request priority review, targeting FDA file acceptance by the end of 2025.

The treatment has received Breakthrough Therapy designation and INOVIO is actively engaging with the FDA to expedite the approval process. The company believes INO-3107 could become the preferred treatment option for RRP patients and healthcare providers.

INOVIO (NASDAQ:INO), a biotechnology company specializing in DNA medicines for HPV-associated diseases, cancer, and infectious diseases, will participate in the H.C. Wainwright 27th Annual Global Investment Conference.

The company will provide a pre-recorded presentation available on demand starting September 5, 2025, at 7:00 AM ET. INOVIO's management team will conduct in-person one-on-one meetings with investors during the conference. The webcast will remain accessible for 90 days through the provided link and INOVIO's Investor Relations Events page.

INOVIO (NASDAQ: INO) reported its Q2 2025 financial results and provided key business updates. The company is on track to submit a Biologics License Application (BLA) for INO-3107 in the second half of 2025, targeting FDA file acceptance by year-end. The company completed design verification testing of CELLECTRA® 5PSP device and requested rolling submission from FDA.

Financial highlights include a reduced net loss of $23.5 million ($0.61 per share) compared to $32.2 million in Q2 2024. R&D expenses decreased to $14.5 million from $23.1 million, and G&A expenses reduced to $8.6 million from $10.2 million. The company raised $22.5 million through a public offering in July 2025, with total cash position of $47.5 million as of June 30, 2025.

Clinical data for INO-3107 showed impressive results, with 86% of patients experiencing 50-100% reduction in surgeries by Year 2, and 50% achieving complete response. The company expects potential commercial launch in 2026 pending FDA approval.

INOVIO (NASDAQ: INO) published promising long-term data in The Laryngoscope for its DNA medicine INO-3107 in treating Recurrent Respiratory Papillomatosis (RRP). The retrospective study showed significant improvements in patient outcomes, with the Overall Response Rate increasing to 86% in Year 2 from 72% in Year 1, and Complete Response rate rising to 50% from 28%.

The mean number of required surgeries decreased substantially from 4.1 per year pre-treatment to 1.7 in Year 1 and 0.9 in Year 2. The study followed 28 patients with a median follow-up of 2.8 years, demonstrating continued improvement trends into Year 3. Importantly, INO-3107 was well-tolerated with no serious adverse events reported.

INOVIO (NASDAQ:INO), a biotechnology company specializing in DNA medicines for HPV-associated diseases, cancers, and infectious diseases, will release its Q2 2025 financial results on August 12, 2025 after market close.

The company will host a conference call and webcast at 4:30 p.m. ET the same day, featuring a general business update and analyst Q&A session. Investors can access the live webcast through INOVIO's investor relations website, with a replay available for 90 days post-event.

INOVIO (NASDAQ:INO), a biotechnology company specializing in DNA medicines, has announced its participation in the upcoming Orphan Drug Summit in Boston, Massachusetts. The company will present on July 16 at 4:30 PM ET, focusing on their DMAb Technology and its transformational potential in rare disease treatment.

The presentation will explore the capabilities of next generation DNA medicine technology in addressing rare diseases, as part of a conference that brings together industry leaders and innovators to discuss technological and manufacturing advancements in the rare disease space.

INOVIO Pharmaceuticals (NASDAQ: INO), a biotechnology company specializing in DNA medicines, has announced the pricing of a $25 million public offering. The offering consists of 14,285,715 shares of common stock along with Series A and Series B warrants, all priced at $1.75 per share.

The warrants allow holders to purchase up to an additional 14,285,715 shares each at an exercise price of $1.75. The underwriters, led by Piper Sandler & Co., have a 30-day option to purchase up to 2,142,857 additional shares and corresponding warrants. The offering is expected to close around July 7, 2025.

INOVIO Pharmaceuticals (NASDAQ: INO), a biotechnology company specializing in DNA medicines, has announced a proposed public offering of common stock and warrants. The offering includes shares of common stock (or pre-funded warrants), along with accompanying Series A and Series B warrants.

The company will grant the underwriter, Piper Sandler & Co., a 30-day option to purchase up to an additional 15% of the securities. The offering will be conducted under a shelf registration statement that was declared effective on January 31, 2024. The final size and terms of the offering will depend on market conditions.